Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development

Core Insights - Roche inaugurated the Institute of Human Biology, marking a significant step in its strategy to enhance drug discovery and development through human model systems [1][2] Investment and Commitment - Roche invests approximately CHF 3.5 billion annually in research, reinforcing its commitment to Switzerland as a global innovation hub [2] - The company is currently investing CHF 1.4 billion in site development in Basel and Kaiseraugst, with a total investment of around CHF 41 billion in Switzerland over the last decade [4][9] Institute of Human Biology (IHB) - The IHB aims to revolutionize medicine by combining human organoid models with artificial intelligence, enhancing the predictability and efficiency of drug development [2] - The institute focuses on advanced human model systems, including organoids and in silico modeling, to better understand human diseases and accelerate therapeutic development [5] - The facility will accommodate up to 250 researchers and is designed to foster interdisciplinary collaboration [3] Research and Development Focus - IHB's research integrates human disease biology, computational biology, and translational bioengineering to create sophisticated models that replicate human disease biology [2] - The institute aims to bridge the gap between fundamental research and industry applications, facilitating rapid translation of scientific discoveries into patient-focused solutions [5]